(Q38012596)

27 August 2017

title

Soluble guanylate cyclase: a potential therapeutic target for heart failure (English)

1 reference

27 August 2017

0 references

1

Mihai Gheorghiade

1 reference

27 August 2017

14

Bertram Pitt

1 reference

27 August 2017

19

Javed Butler

1 reference

27 August 2017

11

Gregg C Fonarow

1 reference

27 August 2017

Umberto Campia

8

0 references

Marco Metra

object named as

Marco Metra

13

0 references

Piotr Ponikowski

object named as

Piotr Ponikowski

15

0 references

Johannes-Peter Stasch

18

object named as

Johannes-Peter Stasch

1 reference

27 August 2017

17

Adriaan A Voors

1 reference

27 August 2017

5

Stephen J Greene

1 reference

27 August 2017

12

Phillip D Levy

1 reference

27 August 2017

4

Lothar Roessig

1 reference

27 August 2017

3

Hani N Sabbah

1 reference

27 August 2017

2

Catherine N Marti

1 reference

27 August 2017

Michael Böhm

6

1 reference

27 August 2017

John C Burnett

7

1 reference

27 August 2017

John G F Cleland

9

1 reference

27 August 2017

Sean P Collins

10

1 reference

27 August 2017

Naoki Sato

16

1 reference

27 August 2017

Academic Research Team in Heart Failure (ART-HF)

20

1 reference

27 August 2017

publication date

1 March 2013

1 reference

27 August 2017

published in

Heart Failure Reviews

1 reference

27 August 2017

volume

18

1 reference

27 August 2017

issue

2

1 reference

27 August 2017

page(s)

123-134

1 reference

Heart Disease and Stroke Statistics--2010 Update: A Report From the American Heart Association

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Factors associated with improvement in ejection fraction in clinical practice among patients with heart failure: findings from IMPROVE HF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Phase III clinical trial end points in acute heart failure syndromes: A virtual roundtable with the acute heart failure syndromes international working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Acute heart failure syndromes: current state and framework for future research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Improving postdischarge outcomes in patients hospitalized for acute heart failure syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Cardiorenal syndrome: new perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Cell death in the pathogenesis of heart disease: mechanisms and significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Nitric oxide's role in the heart: control of beating or breathing?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Myocardial contractile response to nitric oxide and cGMP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Gender-specific hypertension and responsiveness to nitric oxide in sGCalpha1 knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Is oxidative stress a therapeutic target in cardiovascular disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Endothelial dysfunction and vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Hemodynamic stresses induce endothelial dysfunction and remodeling of pulmonary artery in experimental compensated heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Prognostic markers in heart failure--congestion, neurohormones, and the cardiorenal syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Endothelium-dependent dilation of the coronary microvasculature is impaired in dilated cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Impaired endothelium-dependent vasodilation of coronary resistance vessels is associated with exercise-induced myocardial ischemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Influence of nitric oxide synthase and adrenergic inhibition on adenosine-induced myocardial hyperemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Nitric oxide and cardiac function: ten years after, and continuing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Basic mechanisms in heart failure: the cytokine hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Abnormal coronary microvascular endothelial function in humans with asymptomatic left ventricular dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Coronary endothelial dysfunction in patients with acute-onset idiopathic dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Flow-mediated vasodilation predicts outcome in patients with chronic heart failure: comparison with B-type natriuretic peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

A high-fat, refined-carbohydrate diet induces endothelial dysfunction and oxidant/antioxidant imbalance and depresses NOS protein expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Prognostic value of coronary vascular endothelial dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

The prognostic importance of endothelial dysfunction and carotid atheroma burden in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Endothelial nitric oxide synthase overexpression attenuates congestive heart failure in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Nitrosative stress and pharmacological modulation of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Deconstructing endothelial dysfunction: soluble guanylyl cyclase oxidation and the NO resistance syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Structure of cinaciguat (BAY 58-2667) bound to Nostoc H-NOX domain reveals insights into heme-mimetic activation of the soluble guanylyl cyclase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

NO-insensitive sGCbeta1 H105F knockin mice: if NO has no place to go.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

NO-independent stimulators of soluble guanylate cyclase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

NO-independent regulatory site on soluble guanylate cyclase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Biochemistry and pharmacology of novel anthranilic acid derivatives activating heme-oxidized soluble guanylyl cyclase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Cardioprotective effects in aged spontaneously hypertensive rats due to chronic stimulation/activation of sGC without hypotension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Guanylyl cyclase activator ataciguat improves vascular function and reduces platelet activation in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Soluble guanylate cyclase agonists inhibit expression and procoagulant activity of tissue factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Expression and activity of soluble guanylate cyclase in injury and repair of anti-thy1 glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Stimulation of soluble guanylyl cyclase inhibits mesangial cell proliferation and matrix accumulation in experimental glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Enhancing cGMP in experimental progressive renal fibrosis: soluble guanylate cyclase stimulation vs. phosphodiesterase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Additional stimulation of sGC on top of standard treatment with ARB`s may offer a new therapeutic approach for the treatment of diabetic nephropathy resistant to ARB treatment alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

NO-independent activation of soluble guanylate cyclase prevents disease progression in rats with 5/6 nephrectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Acute hemodynamic response to single oral doses of BAY 60-4552, a soluble guanylate cyclase stimulator, in patients with biventricular heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Measuring oxidative burden and predicting pharmacological response in coronary artery disease patients with a novel direct activator of haem-free/oxidised sGC

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-012-9323-1

Blood pressure-independent effect of long-term treatment with the soluble heme-independent guanylyl cyclase activator HMR1766 on progression in a model of noninflammatory chronic renal damage

21 January 2018

1 reference

12 December 2020

Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management

1 reference

12 December 2020

Handbook of Experimental Pharmacology 191. cGMP: generators, effectors and therapeutic implications. Preface

1 reference

12 December 2020

Serum from patients with severe heart failure downregulates eNOS and is proapoptotic: role of tumor necrosis factor-alpha

1 reference

12 December 2020

8-bromo-cGMP reduces the myofilament response to Ca2+ in intact cardiac myocytes

1 reference

12 December 2020

Targeting heme-oxidized soluble guanylate cyclase: solution for all cardiorenal problems in heart failure?

1 reference

12 December 2020

Effects of the nitric oxide donor sodium nitroprusside on intracellular pH and contraction in hypertrophied myocytes

1 reference

12 December 2020

Limb blood flow during exercise is dependent on nitric oxide

1 reference

12 December 2020

Chronic heart failure is associated with vascular remodeling of the brachial artery

1 reference

12 December 2020

Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease

1 reference

12 December 2020

Endothelial dysfunction in chronic heart failure: some new basic mechanisms.

1 reference

12 December 2020

Endothelial Control of Arterial Distensibility Is Impaired in Chronic Heart Failure

1 reference

12 December 2020

Urinary L-type fatty acid-binding protein as a new renal biomarker in critical care

1 reference

12 December 2020

Effects of troglitazone on frequency of coronary vasospastic-induced angina pectoris in patients with diabetes mellitus.

1 reference

12 December 2020

Improvement of endothelial function by chronic angiotensin-converting enzyme inhibition in heart failure : role of nitric oxide, prostanoids, oxidant stress, and bradykinin

1 reference

12 December 2020

Endothelial nitric oxide synthase limits left ventricular remodeling after myocardial infarction in mice.

1 reference

12 December 2020

Acute effects of nitric oxide on left ventricular relaxation and diastolic distensibility in humans. Assessment by bicoronary sodium nitroprusside infusion

1 reference

12 December 2020

Soluble guanylate cyclase stimulation on cardiovascular remodeling in angiotensin II-induced hypertensive rats

1 reference

12 December 2020

Low increase in cGMP induced by organic nitrates and nitrovasodilators improves contractile response of rat ventricular myocytes

1 reference

12 December 2020

Endothelial dysfunction in patients with chronic heart failure is independently associated with increased incidence of hospitalization, cardiac transplantation, or death

1 reference

12 December 2020

Apoptosis in the failing human heart

1 reference

12 December 2020

Pulsatile hemodynamics in congestive heart failure

1 reference

12 December 2020

NO-independent, haem-dependent soluble guanylate cyclase stimulators

1 reference

12 December 2020

Diminished endothelium-derived relaxing factor activity in an experimental model of chronic heart failure

1 reference

12 December 2020

Endothelial dysfunction in patients with heart failure: relationship to disease severity

1 reference

12 December 2020

Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: additive value of flow-mediated dilation to ankle-brachial pressure index

1 reference

12 December 2020

10.1007/S10741-012-9323-1

Identifiers

DOI

1 reference

27 August 2017

1 reference